Robert Kim, MD

Chief Medical Officer

Robert Kim (Bob), MD is Chief Medical Officer. He joined 4DMT in 2020 as SVP, Clinical R&D.

Bob is a board-certified ophthalmologist and retina specialist with two decades of drug development experience. At Genentech, he led clinical development of Lucentis® through to its first approval in wet AMD. As VP and Head of Pharmaceutical Product Development at Alcon/Novartis, he oversaw early development of Beovu® and approvals of Simbrinza® and Pazeo®. Bob was Chief Medical Officer at ViewPoint Therapeutics, Apellis, and Vision Medicines, working on development of compounds that have subsequently been approved in both ophthalmology and hematology (Syfovre®, Empavali®). Bob started out his industry career at Carl Zeiss Meditec as a Senior Scientist focusing on optical coherency tomography (OCT).

Bob completed his residency in ophthalmology at the University of California, San Francisco (UCSF), post-doctoral training in molecular biology at the National Eye Institute (NIH), and retina fellowship training at Moorfields Eye Hospital in London. He received his undergraduate and MD degrees from Brown University, an MBA from UC Berkeley, and a music degree from the Berklee College of Music. Bob was awarded the “Summit of Excellence” Lifetime Achievement Award at the 2023 Clinical Trials at the Summit for his work in ophthalmology.  He is currently an Associate Clinical Professor of Ophthalmology at UCSF.